Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
27.71
+0.58 (2.14%)
At close: Feb 11, 2026, 4:00 PM EST
28.20
+0.49 (1.76%)
After-hours: Feb 11, 2026, 7:47 PM EST
Agios Pharmaceuticals Employees
As of December 31, 2024, Agios Pharmaceuticals had 488 total employees, including 486 full-time and 2 part-time employees. The number of employees increased by 102 or 26.42% compared to the previous year.
Employees
488
Change (1Y)
102
Growth (1Y)
26.42%
Revenue / Employee
$91,785
Profits / Employee
-$822,264
Market Cap
1.62B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 488 | 102 | 26.42% | 486 | 2 |
| Dec 31, 2023 | 386 | -7 | -1.78% | 383 | 3 |
| Dec 31, 2022 | 393 | 1 | 0.26% | 389 | 4 |
| Dec 31, 2021 | 392 | -170 | -30.25% | 390 | 2 |
| Dec 31, 2020 | 562 | 26 | 4.85% | 562 | 0 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 493 |
| Nurix Therapeutics | 317 |
| Relay Therapeutics | 188 |
| Celldex Therapeutics | 186 |
| Enliven Therapeutics | 65 |
| Tyra Biosciences | 60 |
| Oculis Holding AG | 49 |
| Sionna Therapeutics | 48 |
AGIO News
- 16 days ago - Agios to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast on February 12 at 8:00 a.m. ET - GlobeNewsWire
- 4 weeks ago - Agios Pharmaceuticals, Inc. (AGIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Agios Outlines 2026 Strategic Priorities and Key Milestones to Accelerate Rare Disease Portfolio Growth - GlobeNewsWire
- 5 weeks ago - Agios to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026 - GlobeNewsWire
- 7 weeks ago - Agios Pharmaceuticals, Inc. (AGIO) Discusses FDA Approval of AQVESME for Anemia in Alpha and Beta Thalassemia Transcript - Seeking Alpha
- 7 weeks ago - Agios Pharma Stock: A Buy After FDA Approves Aqvesme - Seeking Alpha
- 7 weeks ago - Agios Pharma jumps 15% as FDA expands use of anaemia drug mitapivat - Invezz
- 7 weeks ago - Agios Pharma shares jump as US FDA expands approval for its blood disorder drug - Reuters